Cargando…
US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018
IMPORTANCE: The US Food and Drug Administration (FDA) grants accelerated approval according to surrogate measures of numerous drug indications for serious or life-threatening illnesses such as infectious diseases and cancer. Investigators, including the FDA, have evaluated the program’s regulatory a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463606/ https://www.ncbi.nlm.nih.gov/pubmed/36083581 http://dx.doi.org/10.1001/jamanetworkopen.2022.30973 |
_version_ | 1784787428079304704 |
---|---|
author | Omae, Kenji Onishi, Akira Sahker, Ethan Furukawa, Toshi A. |
author_facet | Omae, Kenji Onishi, Akira Sahker, Ethan Furukawa, Toshi A. |
author_sort | Omae, Kenji |
collection | PubMed |
description | IMPORTANCE: The US Food and Drug Administration (FDA) grants accelerated approval according to surrogate measures of numerous drug indications for serious or life-threatening illnesses such as infectious diseases and cancer. Investigators, including the FDA, have evaluated the program’s regulatory and clinical consequences in oncology, but evaluation of nononcology drugs is lacking. OBJECTIVE: To evaluate the accelerated approval program for nononcology drug indications over a period of 26 years. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used publicly available data on FDA nononcology drug indications granted accelerated approval from June 1992 through May 2018, with preapproval and confirmatory trials for approved drugs. Data were analyzed from February to April 2022. MAIN OUTCOMES AND MEASURES: The study estimated the median time from accelerated approval to occurrence of regulatory outcomes such as regular approval conversion, postapproval boxed warning label changes, confirmatory trial completion, and confirmatory trial results publication. RESULTS: The FDA granted accelerated approval of 48 drugs for 57 nononcology indications, including 23 (40%) HIV treatments, supported by 93 preapproval trials. Forty-three indications (75%) were converted to regular approval at a median time of 53.1 (95% CI, 38.7 to 70.2) months from accelerated approval. There were postapproval label modifications on boxed warnings in 27 indications (47%) with a median time of 248.6 (95% CI, 51.8 to not estimable) months from accelerated approval. Of the 86 required confirmatory trials, 17 (20%) had not fulfilled the postapproval requirements. The median time to confirmatory trial completion was 39.4 (95% CI, 30.7 to 47.9) months. Nine trials (10%) failed to verify clinical efficacy, but only 1 of 8 indications assessed (2%) was withdrawn owing to the failed confirmatory trial, which was 136 months after approval. Results were published in 56 completed confirmatory trials (65%), with the median time being 52.5 (95% CI, 35.6 to 82.2) months from accelerated approval to publication. CONCLUSIONS AND RELEVANCE: Although the program expedited the approval of nononcology drug indications by a median (IQR) of 53.1 (26.8-133.2) months, safety-related label modifications were often added in boxed warnings after approval, and clinical efficacy was sometimes not confirmed. The study findings and long follow-up period suggest that comprehensive evaluation of such drugs may take more than a decade. |
format | Online Article Text |
id | pubmed-9463606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-94636062022-09-24 US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018 Omae, Kenji Onishi, Akira Sahker, Ethan Furukawa, Toshi A. JAMA Netw Open Original Investigation IMPORTANCE: The US Food and Drug Administration (FDA) grants accelerated approval according to surrogate measures of numerous drug indications for serious or life-threatening illnesses such as infectious diseases and cancer. Investigators, including the FDA, have evaluated the program’s regulatory and clinical consequences in oncology, but evaluation of nononcology drugs is lacking. OBJECTIVE: To evaluate the accelerated approval program for nononcology drug indications over a period of 26 years. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used publicly available data on FDA nononcology drug indications granted accelerated approval from June 1992 through May 2018, with preapproval and confirmatory trials for approved drugs. Data were analyzed from February to April 2022. MAIN OUTCOMES AND MEASURES: The study estimated the median time from accelerated approval to occurrence of regulatory outcomes such as regular approval conversion, postapproval boxed warning label changes, confirmatory trial completion, and confirmatory trial results publication. RESULTS: The FDA granted accelerated approval of 48 drugs for 57 nononcology indications, including 23 (40%) HIV treatments, supported by 93 preapproval trials. Forty-three indications (75%) were converted to regular approval at a median time of 53.1 (95% CI, 38.7 to 70.2) months from accelerated approval. There were postapproval label modifications on boxed warnings in 27 indications (47%) with a median time of 248.6 (95% CI, 51.8 to not estimable) months from accelerated approval. Of the 86 required confirmatory trials, 17 (20%) had not fulfilled the postapproval requirements. The median time to confirmatory trial completion was 39.4 (95% CI, 30.7 to 47.9) months. Nine trials (10%) failed to verify clinical efficacy, but only 1 of 8 indications assessed (2%) was withdrawn owing to the failed confirmatory trial, which was 136 months after approval. Results were published in 56 completed confirmatory trials (65%), with the median time being 52.5 (95% CI, 35.6 to 82.2) months from accelerated approval to publication. CONCLUSIONS AND RELEVANCE: Although the program expedited the approval of nononcology drug indications by a median (IQR) of 53.1 (26.8-133.2) months, safety-related label modifications were often added in boxed warnings after approval, and clinical efficacy was sometimes not confirmed. The study findings and long follow-up period suggest that comprehensive evaluation of such drugs may take more than a decade. American Medical Association 2022-09-09 /pmc/articles/PMC9463606/ /pubmed/36083581 http://dx.doi.org/10.1001/jamanetworkopen.2022.30973 Text en Copyright 2022 Omae K et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Original Investigation Omae, Kenji Onishi, Akira Sahker, Ethan Furukawa, Toshi A. US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018 |
title | US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018 |
title_full | US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018 |
title_fullStr | US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018 |
title_full_unstemmed | US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018 |
title_short | US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018 |
title_sort | us food and drug administration accelerated approval program for nononcology drug indications between 1992 and 2018 |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463606/ https://www.ncbi.nlm.nih.gov/pubmed/36083581 http://dx.doi.org/10.1001/jamanetworkopen.2022.30973 |
work_keys_str_mv | AT omaekenji usfoodanddrugadministrationacceleratedapprovalprogramfornononcologydrugindicationsbetween1992and2018 AT onishiakira usfoodanddrugadministrationacceleratedapprovalprogramfornononcologydrugindicationsbetween1992and2018 AT sahkerethan usfoodanddrugadministrationacceleratedapprovalprogramfornononcologydrugindicationsbetween1992and2018 AT furukawatoshia usfoodanddrugadministrationacceleratedapprovalprogramfornononcologydrugindicationsbetween1992and2018 |